Ancillary approaches to plasminogen activators
Article first published online: 20 SEP 2012
© 2012 New York Academy of Sciences.
Annals of the New York Academy of Sciences
Volume 1268, Thrombolysis and Acute Stroke Treatment pages 113–119, September 2012
How to Cite
Bavarsad Shahripour, R. and Alexandrov, A. V. (2012), Ancillary approaches to plasminogen activators. Annals of the New York Academy of Sciences, 1268: 113–119. doi: 10.1111/j.1749-6632.2012.06688.x
- Issue published online: 20 SEP 2012
- Article first published online: 20 SEP 2012
- tissue plasminogen activator;
- combination therapy
Acute ischemic stroke develops from an interruption in focal cerebral blood flow. In many cases, it is caused by an acute thromboembolism. Although systemic fibrinolytic therapy for acute ischemic stroke has been a significant breakthrough in the management of this disease, additional agents and methods that could improve or restore cerebral flow are necessary. Similarly to findings in acute myocardial infarction, combination pharmacotherapy has the potential to improve current thrombolytic treatment in acute ischemic stroke. In recent years, research efforts were directed toward various combination therapy with pharmacological and nonpharmacological methods. Several trials tested tissue plasminogen activator (t-PA) in combination with antiplateletes and anticoagulants. Combination of t-PA with nonpharmacological agents included sonothrombolysis (amplifying the thrombolytic effect), laser (neuro-recovery), hypothermia (cytoprotection and decreasing brain swelling), and blood flow augmentation (increasing residual flow and recruitment of collateral vessels). This paper will review ongoing clinical trials and safety of these promising combinatory treatments.